GILD

Gilead Sciences
D

GILD

Arincen87/100B
166.870
USD
-0.73
(-0.44%)
Pre Open·168.040USD+1.170(+0.70%)
Last updated: · Delayed 15 min
Q4 FY2026 · Earnings report
EPS estimate 1.39Revenue estimate 8.28B
OverviewFinancialsForecastEarningsDividendsCompany

Gilead Sciences executives and insider trading

Daniel O'Day sold 505,490 shares for 75.73M USD in 32 sales over the last twelve months, the last on 5 November 2026, and bought none on the open market.

Over the last twelve months Gilead Sciences's insiders sold 769,247 shares for 111.16M USD in 83 sales on the open market, and bought 0 shares in 0 purchases.

Insiders over the last twelve months

Insider sales
83
Shares sold
769,247
Value sold
111.16M USD
Insider purchases
0

Insiders buying against selling

Bought on the market
Sold on the market
0
1 week
22.24M USD
0
1 month
25.96M USD
0
3 months
38.95M USD
0
6 months
49.82M USD
0
1 year
111.16M USD
0
2 years
198.40M USD
Sold, decided at the timeSold under a Rule 10b5-1 plan set in advance

Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).

Executives and directors

The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.

NamePositionAgeShares sold (12 months)Value sold (12 months)Shares bought (12 months)Last saleShares held after
Daniel O'Day CEOChairman & Chief Executive Officer61505,49075.73M USD—5 Nov 2026561,493
Johanna Mercier Chief Commercial & Corporate Affairs Officer56136,00018.64M USD—15 Oct 2026113,684
Deborah H Telman EVP, Corporate Affairs & GC—53,6466.59M USD—12 Nov 202579,641
Andrew D. Dickinson Executive VP & CFO5635,5004.85M USD—15 Oct 2026161,096
Anthony Welters Director—18,0002.68M USD—26 Aug 202623,176
Jeffrey Bluestone Director—15,0001.97M USD—20 Aug 202611,882
Kelly A. Kramer Director—5,611713.19K USD—28 Nov 20254,144

Insider sales and purchases by quarter

How many insider sales and purchases were reported each quarter.

Insider sales Insider purchases

Every insider transaction

Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.

DateNameTransactionSharesPriceValueShares held afterFiling
5 Nov 2026Daniel O'DaySale9,810175.171.72M USD551,683Form 4
4 Nov 2026Daniel O'DaySale102,619175.1617.98M USD551,683Form 4
2 Nov 2026Daniel O'DaySale1,600167.40267.84K USD565,083Form 4
2 Nov 2026Daniel O'DaySale1,700168.10285.77K USD563,383Form 4
2 Nov 2026Daniel O'DaySale1,904169.27322.30K USD561,479Form 4
2 Nov 2026Daniel O'DaySale7,796170.351.33M USD553,683Form 4
2 Nov 2026Daniel O'DaySale2,000171.06342.13K USD551,683Form 4
30 Oct 2026Daniel O'DaySale15,881175.252.78M USD566,683Form 4
15 Oct 2026Andrew D. DickinsonSale3,000156.22468.66K USD161,096Form 4
15 Oct 2026Johanna MercierSale3,000156.22468.66K USD113,684Form 4
1 Oct 2026Daniel O'DaySale12,000147.721.77M USD569,683Form 4
1 Oct 2026Daniel O'DaySale3,000148.63445.88K USD566,683Form 4
15 Sept 2026Andrew D. DickinsonSale3,000145.29435.87K USD164,096Form 4
15 Sept 2026Johanna MercierSale1,600143.69229.91K USD118,084Form 4
15 Sept 2026Johanna MercierSale800144.46115.57K USD117,284Form 4

Common questions about Gilead Sciences's executives and insiders

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.